Women's participation in breast cancer screening in France - An ethical approach

BMC Medical Ethics

Volumn 15, Issue 1, 2014, Pages

  Moutel, Grégoire ^a,b   Duchange, Nathalie ^c   Darquy, Sylviane ^c   De Montgolfier, Sandrine ^d   Papin Lefebvre, Frédérique ^e,f   Jullian, Odile ^g   Viguier, Jérôme ^g   Sancho Garnier, Hélène ^h  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b EHESP SCHOOL OF PUBLIC HEALTH   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d School for Advanced Studies in the Social Sciences   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers'   (France)

^g INSTITUT NATIONAL DU CANCER   (France)

^h UNIV MONTPELLIER   (France)

Author keywords

Breast cancer screening; Ethics; Information; Organized programme

Indexed keywords

ACCESS TO INFORMATION; AGED; BREAST NEOPLASMS; DECISION MAKING; DOCTOR PATIENT RELATION; EARLY CANCER DIAGNOSIS; ETHICS; FEMALE; FRANCE; HUMAN; INFORMED CONSENT; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MORALITY; PATIENT ATTITUDE; PATIENT PARTICIPATION; PERSONAL AUTONOMY; PROCEDURES; PUBLIC HEALTH;

ACCESS TO INFORMATION; AGED; BREAST NEOPLASMS; CHOICE BEHAVIOR; EARLY DETECTION OF CANCER; FEMALE; FRANCE; HUMANS; INFORMED CONSENT; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MORALS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PARTICIPATION; PERSONAL AUTONOMY; PHYSICIAN-PATIENT RELATIONS; PUBLIC HEALTH;

EID: 84906924158     PISSN: None     EISSN: 14726939     Source Type: Journal    
DOI: 10.1186/1472-6939-15-64     Document Type: Review

References (47)

1. Principles and Practice of Mass Screening for Disease. Wilson JMG, Jungner G, Public Health Papers Geneva: WHO 1968 34 http://apps.who.int/iris/handle/10665/37650
2. Éthique et Dépistage Organisé du Cancer du sein en France. Rapport du Groupe de réflexion sur l'éthique du dépistage (GRED), Boulogne-Billancourt: INCa, INCa, Collection Etats des lieux & des Connaissances. 2012 http://www.e-cancer.fr/
3. Estimation Nationale de l'incidence et de la Mortalité par Cancer en France entre 1980 et 2012. Binder-Foucard F, Belot A, Delafosse P, Remontet L, Woronoff AS, Partie 1-Tumeurs Solides. InVS. 2013 http://www.invs.sante.fr
4. Cancer incidence and mortality in France over the period 1980-2005. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Rev Epidemiol Sante Publique 2008 56 159 175
5. Breast Cancer Screening. International Agency for Research on Cancer (IARC), IARC Handbooks of Cancer Prevention, Volume 7 Lyon: IARC Press 2002 http://www.iarc.fr
6. Recommendations on cancer screening in the European Union. Advisory Committee on Cancer Prevention, Eur J Cancer 2000 36 1473 1478
7. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. International Agency for Research on Cancer (IARC), Fourth 2006 ec.europa.eu/heath
8. Evolution des taux de Participation Au Programme National de Dépistage Organisé du Cancer du sein par classe d'âge, depuis 2005. Institut National de Veille Sanitaire (InVS), 2013 http://www.invs.sante.fr
9. La Participation au Dépistage du Cancer du sein chez les Femmes de 50 à 74 ans en France: Situation Actuelle et Perspectives d'évolution. Haute Autorite de Santé (HAS), Saint-Denis 2011 http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-02/argumentaire---participation-depistage-cancer-du-sein-2012-02-02-15-27-14-245.pdf
10. Les Français face au Dépistage des Cancers. INCa, Collection Enquêtes et Sondages Boulogne Billancourt: INCa, INCa, 2009 http://www.e-cancer.fr/
11. Are breast cancer screening practices associated with sociodemographic status and healthcare access? Analysis of a French cross-sectional study. Duport N, Ancelle-Park R, Boussac-Zarebska M, Uhry Z, Bloch J, Eur J Cancer Prev 2008 17 218 224
12. Should we screen for breast cancer? McPherson K, BMJ 2010 341 7767 233
13. Screening for breast cancer with mammography. Gøtzsche PC, Jørgensen KJ, Cochrane Database Syst Rev 2013 6 D001877
14. Is screening for breast cancer with mammography justifiable? Gøtzsche PC, Olsen O, Lancet 2000 355 129 134
15. Cochrane review on screening for breast cancer with mammography. Olsen O, Gøtzsche PC, Lancet 2001 358 1340 1342
16. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L, Ann Intern Med 2009 151 727 737 W237-42
17. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Peto R, Boreham J, Clarke M, Davies C, Beral V, Lancet 2000 355 9217 1822
18. Breast cancer mortality in organised mammography screening in Denmark: comparative study. Jørgensen KJ, Zahl PH, Gøtzsche PC, BMJ 2010 340 1241
19. Effect of screening mammography on breast-cancer mortality in Norway. Kalager M, Zelen M, Langmark F, Adami HO, N Engl J Med 2010 363 1203 1210
20. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. Autier P, Boniol M, Gavin A, Vatten LJ, BMJ 2011 343 4411
21. The decline in breast cancer mortality in Europe: An update (to 2009). Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, La Vecchia C, Breast 2011 21 1 77 82
22. Adjuvant therapy, not mammographic screening, accounts for most of the observed breast cancer specific mortality reductions in Australian women since the national screening program began in 1991. Burton RC, Bell RJ, Thiagarajah G, Stevenson C, Breast Cancer Res Treat 2012 131 3 949 955
23. The benefits and harms of breast cancer screening: an independent review. Independent UK Panel on Breast Cancer Screening, Lancet 2012 380 9855 1778 1786
24. The benefits and harms of breast cancer screening: an independent review. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Br J Cancer 2013 108 2205 2240
25. Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. Seigneurin A, François O, Labarère J, Oudeville P, Monlon J, BMJ 2011 343 7017
26. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, J Med Screen 2012 19 Suppl 1 42 56
27. The benefits and harms of breast cancer screening. Gøtzsche PC, Jørgensen KJ, Lancet 2013 9 381(9869) 799
28. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. Jørgensen KJ, Gøtzsche PC, BMJ 2009 9 339:b2587
29. False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. Hofvin S, Ponti A, Patnick J, Ascunce N, Njor S, J Med Screen 2012 19 57 66
30. Comparison of interval breast cancer rates for two-versus single-view screening mammography: a population-based study. Seigneurin A, Exbrayat C, Labarère J, Colonna M, Breast 2009 18 5 284 288
31. Mammography screening and trust: the case of interval breast cancer. Solbjør M, Skolbekken JA, Sætnan AR, Hagen AI, Forsmo S, Soc Sci Med 2012 75 10 1746 1752
32. Risk of radiation-induced breast cancer from mammographic screening. Yaffe MJ, Mainprize JG, Radiology 2011 258 98 105
33. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Radiat Res 2002 158 2 220 235
34. Council Directive 97/43/Euratom of 30 June 1997 on health protection of individuals against the dangers of ionizing radiation in relation to medical exposure, and repealing Directive 84/466/Euratom. European Commission, Official journal NO. L 180, 09/07/1997 P. 0022-0027
35. Women's views on overdiagnosis in breast cancer screening: a qualitative study. Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, BMJ 2013 346 158 f158
36. Communicating the balance sheet in breast cancer screening. Giordano L, Cogo C, Patnick J, Paci E, J Med Screen 2012 19 1 67 71
37. Breast cancer screening in women aged 50-74 years: is there room for improvement? Morère JF, Pivot X, Viguier J, Blay JY, Calazel-Benque A, Eur J Canc 2011 20 Suppl 1 8 S12
38. INCa, Dépistage Organisé du Cancer du sein, Avantages et Inconvénients INCa: http://www.e-cancer.fr/depistage/depistage-du-cancer-du-sein/espace-grand-public/avantages-et-inconvenients-du-depistage
39. Informed Choice about Cancer Screening. Approach to Developing Information about NHS Cancer Screening Programmes. National Health Service (NHS), http://www.informedchoiceaboutcancerscreening.org/wp-content/uploads/2012
40. Women "jurors" are asked how to present risk-benefit ratio of breast cancer screening. Hawkes N, BMJ 2012 345 7886
41. Principles of Biomedical Ethics. Beauchamp TL, Childress JF, New York: Oxford University Press 6 2004 1 1979
42. French Law n°2002-303 of March 4, 2002 on the Rights of Sick Persons http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000227015
43. The place of consent in relationships between physicians and patients: a philosophical point of view. Marzano M, Presse Med 2013 42 6 12
44. Patient perspectives on information and choice in cancer screening: a qualitative study in the UK. Jepson RG, Hewison J, Thompson A, Weller D, Soc Sci Med 2007 65 5 890 899
45. Éthique et santé publique: Quelle place pour l'autonomie? Gravel S, Doucet H, Battaglini A, Laudy D, Bouthillier ME, Boucheron L, Fournier M, Ethique publique 2010 12 1 1226 1250
46. Systematic Mammography Screening. Swiss Medical Board, http://www.medical-board.ch/fileadmin/docs/public/mb/Fachberichte/2013-12-15-Bericht-Mammographie-Final-Kurzfassung-e.pdf
47. Abolishing mammography screening programs? A View from the Swiss Medical Board. Biller-Andorno N, Jüni P, N Engl J Med 2014 370 21 1965 1967